Your browser doesn't support javascript.
loading
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin, Jinhyuk; Yemelyanenko, Julia; Chao, Xue; Klarenbeek, Sjoerd; Opdam, Mark; Malka, Yuval; Hoekman, Liesbeth; Kruger, Dinja; Bleijerveld, Onno; Brambillasca, Chiara S; Sprengers, Justin; Siteur, Bjørn; Annunziato, Stefano; van Haren, Matthijs J; Martin, Nathaniel I; van de Ven, Marieke; Peters, Dennis; Agami, Reuven; Linn, Sabine C; Boven, Epie; Altelaar, Maarten; Jonkers, Jos; Zingg, Daniel; Wessels, Lodewyk F A.
Afiliação
  • Bhin J; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Yemelyanenko J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Chao X; Oncode Institute , Utrecht, Netherlands.
  • Klarenbeek S; Department of Biomedical System Informatics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Opdam M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Malka Y; Oncode Institute , Utrecht, Netherlands.
  • Hoekman L; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Kruger D; Oncode Institute , Utrecht, Netherlands.
  • Bleijerveld O; Experimental Animal Pathology, Netherlands Cancer Institute , Amsterdam, Netherlands.
  • Brambillasca CS; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Sprengers J; Oncode Institute , Utrecht, Netherlands.
  • Siteur B; Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Annunziato S; Proteomics Facility, Netherlands Cancer Institute , Amsterdam, Netherlands.
  • van Haren MJ; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Martin NI; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, Amsterdam, Netherlands.
  • van de Ven M; Proteomics Facility, Netherlands Cancer Institute , Amsterdam, Netherlands.
  • Peters D; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Agami R; Oncode Institute , Utrecht, Netherlands.
  • Linn SC; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute , Amsterdam, Netherlands.
  • Boven E; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute , Amsterdam, Netherlands.
  • Altelaar M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Jonkers J; Oncode Institute , Utrecht, Netherlands.
  • Zingg D; Biological Chemistry Group, Institute of Biology Leiden, Leiden University , Leiden, Netherlands.
  • Wessels LFA; Biological Chemistry Group, Institute of Biology Leiden, Leiden University , Leiden, Netherlands.
J Exp Med ; 220(11)2023 11 06.
Article em En | MEDLINE | ID: mdl-37642941
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Animals / Female / Humans Idioma: En Revista: J Exp Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Animals / Female / Humans Idioma: En Revista: J Exp Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda